Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Completed Initiated Aug 17, 2023 (3 years ago)

Sabril (vigabatrin)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Cross contamination with other products

Cause type: Cross-contamination

Traces of another drug - most often penicillin - got into the product from shared equipment or facilities. Even trace penicillin can trigger a severe allergic reaction in someone who was never meant to receive it. All cross-contamination recalls.

What was recalled

Sabril (vigabatrin) for Oral Solution, 500 mg, 50 Packets, Rx only, Manufactured by: Patheon, Cincinnati, OH 45237, NDC 67386-211-65

Affected NDC 67386-0211-65

Compare with the code on your package — it is the most precise check available.

Drug: Vigabatrin

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Sabril
vigabatrin
NDC 67386-0211
50 mg/mL Powder, for Solution
Oral
Lundbeck Pharmaceuticals LLC Rx
Recalling firm
Lundbeck LLC
NDC code
67386-211-65
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1142-2023 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now completed, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Vigabatrin recalls

See all
Class II · Moderate risk

Vigabatrin for Oral Solution

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-521-63 D-0418-2023

Other cross-contamination recalls from 2023

All cross-contamination recalls
Class I · High risk

Brexafemme

Cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance with ezetimibe (a non-antibacterial beta-lactam compound).

Completed Cross-contamination Scynexis, Inc. NDC 75788-115-04 D-0042-2024
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7596-3 D-0506-2023
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7595-3 D-0505-2023
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7594-3 D-0504-2023